References
- Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565–1574.
- Werida RH, El-Okaby AM, El-Khodary NM. Evaluation of levofoxacin utilization in intensive care units of tertiary care hospital: a retrospective observational study. Drugs Ther Perspect. 2020;36(1):33–39.
- Viasus D, Gaia V, Manzur-Barbur C, et al. Legionnaires’ disease: update on diagnosis and treatment. Infect Dis Ther. 2022;11(3):973–986.
- Croom KF, Goa KL. Levofloxacin a review of its use in the treatment of bacterial infections in the United States. Drugs. 2003;63(24):2769–2802.
- Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148(7):1340–1352.e7.
- Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63(1):52–61.
- Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966; quiz 967.
- Moreno-Torres M, Quintás G, Castell JV. The potential role of metabolomics in drug-induced liver injury (Dili) assessment. Metabolites. 2022;12(6):564.
- Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14.
- Miller JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013;3(7):a011866–a011866.
- Sagon AL. Jr. Absolute erythrocytosis as a result of smoking. Clin Res. 1973;21:566–571.
- Kohgo Y, Ikuta K, Ohtake T, et al. Body iron metabolism and pathophysiology of iron overload. Int J Hematol. 2008;88(1):7–15.
- Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G847–51.
- Tamai T, Uto H, Takami Y, et al. Serum manganese superoxide dismutase and thioredoxin are potential prognostic markers for hepatitis C virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17(44):4890–4898.
- Melhem A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants results of a phase I clinical trial. J Clin Gastroenterol. 2005;39(8):737–742.
- Tukov FF, Luyendyk JP, Ganey PE, et al. The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci. 2007;100(1):267–280.
- Yazici C, Mutlu E, Bonkovsky HL, et al. Risk factors for severe or fatal drug-induced liver injury from amoxicillin-clavulanic acid. Hepatol Res. 2015;45(6):676–682.
- Coppola L, Caserta F, De Lucia D, et al. Blood viscosity and aging. Arch Gerontol Geriatr. 2000;31(1):35–42.
- Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13(32):4295–4305.
- Hirata K, Takagi H, Yamamoto M, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in japanese patients: a preliminary case–control study. Pharmacogenomics J. 2008;8(1):29–33.